# HBOT

## HBOT

#### UHMS Indications

- 1. Air or Gas Embolism
- 2. CO poisoning
- 3. Clostridial myositis and myonecrosis (Gas Gangrene)
- 4. Crush injury, compartment syndrome, other acute traumatic ischemias
- 5. DCS
- 6. Arterial insufficiencies
- 7. Severe anemia
- 8. Intracranial abscess
- 9. Necrotizing soft tissue infections
- 10. Osteomyelitis (refractory)
- 11. Delayed radiation injury (soft tissue, bony necrosis)
- 12. Compromised grafts and flaps
- 13. Acute thermal burn injury
- 14. Idiopathic sudden sensorineural hearing loss (new Oct 2011)

- CAF Treatment Tables
  - Limits due to OxTox (decreased with air breaks)
  - If TT stopped due to CNS OxTox, allow 15 mins after sx resolved, then resume schedule at point of interruption
  - Tx repeated until resolution or plateau
  - Contraindications almost all relative (depends on indication)
    - Largely same as diving
  - Other common treatment tables:
    - USN, Comex, Catalina, CO poisoning
    - Proprietary commercial tables

## HBOT Mechanisms

- Bubble Compression (Boyle's Law)
- Hyperoxygenation (Henry's Law)
  - 10-15x increase in plasma O2
  - 2-4 x increase in O2 diffusion capacity from capillaries
- Gas Gradient support gas washout, prevent additional uptake of inert gas during HBOT
- Antimicrobial effect
  - Inhibit clostridial alpha toxin
  - Anaerobic bacteriostasis
  - enhance antibiotic activity,
  - improve PMN fx

- Blunt ischemia-reperfusion injury
  - Attenuates PMB-endothelial interaction
  - Prevent lipid peroxidation
- Decrease edema
  - Vasoconstriction (while tissues remain hyper-oxygenated)
- Angiogenesis/Wound healing
  - Stimulate vasculogenic stem cell mobilization
  - Increase growth factor synthesis
  - Stim fibroblast proliferation
  - Angiogenesis, reversal of tissue hypoxia

## Adjuncts

#### NSAIDs

- No diff in final outcome, but with tenoxicam divers needed fewer TT
- NNT ~4-5
- Heliox
  - May decrease # of TT required
- Lidocaine may have neuroprotective effect
  - Insufficient evidence to support routine use
- Perfluorocarbons increased O<sub>2</sub> delivery, N<sub>2</sub> removal
  - Animal models only so far
- Not recommended: steroid, ASA, Heparin (unless DVT prophylaxis @24hrs)

- Other considerations
  - Hydration, food
  - Urinary catheter
  - DVT prophylaxis
  - Hospital admission
  - Specialists consults (i.e. neuro)



B-GG-380-000/FP-005

Figure 3-2-2 Decompression Illness





#### Treatment Table Summary

Table	Indications
5	Type 1 DCS only if sx completely resolved during transport to RCC Recurrence Type 1 Sx (complete resolved after 1x O₂ period at 18msw) Omitted-D, uncontrolled ascent/blow-up – for Asx if omitted D ≤30 mins)
6	DCS, AGE responding to initial 18msw RCC Omitted D, uncontrolled ascent/blow-up: Asx individual with ≥ 30 mins
6 Mod	Extension of TT6, if patient remains sx by end of 2 <sup>nd</sup> O <sub>2</sub> period at 18msw
6A	Severe AGE/DCS deteriorating or not responding at 18msw, resolving @50msw
6A Mod	Extension of TT6A, if patient remains sx by end of 2 <sup>nd</sup> O <sub>2</sub> period @18msw
7	Heroic measure, used in extreme cases
8	Deteriorating severe AGE/DCS sx @50msw, recurrence of severe AGE/DCS during deco from 50msw-18msw etc.







#### B-GG-380-000/FP-005







